

A rare case of translocation (12;22) (p13;Q) in Ewing's sarcoma

S. K. Kousar Jahan¹,
Mangala Gowri Mayanna²,
B. L. Kavitha²,
Akkamahadevi Patil²,
Prasanna Kumari²

¹Department of Molecular Medicine, Cytogenetics Laboratory, Al Jawhara Centre, Arabian Gulf University, Manama, Kingdom of Bahrain, ²Department of Pathology Cytogenetics Unit, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India

Address for correspondence:
Dr. Syeeda Khursheed Kousar Jahan,
Cytogenetics Laboratory,
Al Jawhara Center for Molecular Medicine and Inherited Disorders,
Building 61, King Abdul Aziz Avenue, Manama, Al Suqayyah,
Block 328, Arabian Gulf University,
Kingdom of Bahrain.
E-mail: skkousar@yahoo.com

ABSTRACT

Cytogenetic or immunohistochemical studies are often required to differentiate Ewing's sarcoma (ES) from other small round cell tumors. Herein we report a case of 13-year-old boy who presented with a large presacral lesion. Hemogram and biochemical parameters were normal except lactate dehydrogenase showing value of 96.40 IU/L, magnetic resonance imaging of the spine showed a large mass in presacral lesion (8 cm × 7 cm × 9 cm), with destruction of the sacrum (S2 S3 and S4) with interspinal extension. Bone scan showed multiple pelvic bone lesions, radiograph of chest, ultrasound of abdomen, pelvis and electrocardiogram were within normal limits. Bone marrow was not involved. Cells from the fine needle aspirate were cultured for short term using RPMI medium and karyotype obtained showed a t(12;22)(p12;q12) instead of the classic t(11;22). Diagnosis of ES was also confirmed by studies using immunohistochemistry for MIC2 which was positive, synaptophysin was inconclusive and leukocyte common antigen, desmin negative. This case provides evidence of the importance of chromosome 22, in the etiology of the disease.

Key words: Cytogenetics, Ewing's sarcoma, karyotype

INTRODUCTION

The t(11;22)(q24;q12) is the most common translocation for ES and is present in more than 85% of cases.^[1] This translocation leads to an EWS/FLI1 fusion gene in all cases. In a few instances, complex translocations, involving chromosomes 11 and 22 and a third chromosome or other variant translocations not involving chromosome 11 also have been reported.^[2] They are molecularly characterized by expression of chimeric transcripts generated by specific chromosomal translocations, most commonly involving fusion of the EWS gene to a member of the Ewing tumors family of transcription factors, which include FLI1, ERG, ETV1, E1AF and FEV.^[3] Sarcomas are a heterogeneous group of cancers derived from the connective tissue lineage. The

etiology of these tumors is unknown, and the vast majority of the cases occur without known hereditary factors. In the last two decades, the finding of specific acquired chromosomal alterations in sarcomas has helped in many cases to understand the underlying genetic basis of this tumor.^[4]

Ewing's sarcoma (ES), peripheral primitive neuroectodermal tumors (pPNETs) and Askin tumors are referred to as Ewing tumors (ETs). ES is the second most common malignant bone tumor in children and young adults, occurring with a male/female ratio of 1.5:1.^[1,5] The most frequent primary site is the femur, followed by the pelvis arising from the ileum, ischium, pubic bone, or sacrum. Tumors may also originate in the tibia, fibula, or the bones of the feet. ES is the result of a translocation between chromosome 11 and 22, which fuses the *EWS* gene on chromosome 22 to the *FLI1* gene on chromosome 11. *EWS/FLI1* functions as the master regulator.^[6]

A review of literature shows the chromosome partners involved in translocation with chromosome 22 in sarcomas are 1, 2, 4, 6, 7, 9, 11, 12, 17, 19, 20 and 21 as shown in the Chart 1. Nearly 85% cases of ES contain the t(11;22)(q24;q12) Chromosomal translocation that encodes the EWS/FLI

Access this article online

Quick Response Code:



Website:
www.ijmpo.org

DOI:
10.4103/0971-5851.133730



Figure 2a: GTG banded metaphase



Figure 2b: GTG-banded karyotype showing 46, XY, t(12;22)(p13;q12). Arrows indicate break points

Table: 1 The frequency of t(11;22) and its variants in ES

Translocation	Gene fusion product	Frequency in Ewing tumors %
t(11;22)(q24;q12)	EWS-Flt1	>90
t(21;22)(q22;q12)	EWS-ERG	5
t(17;22)(q12;q12)	EWS-E1AF	<1
t(2;22)(q33;q12)	EWS-FEV	<1
t(7;22)(p22;q12)	EWS-ETV1	1
t(4;22)(q31;q12)	EWSR1-SMARCA5	1

ES – Ewing's sarcoma; EWSR1 – Ewing sarcoma region 1

The incidence of classical t(11;22) in ES is around 90% approximately. Involvement of other chromosomes participating in translocation with 22 such as 21 is 5%, 2%, 4%, 7% and 17% are 1%, respectively and are rare [Table 1].

The present case adds on to this rare list of abnormalities in ES. The *EWS-FLI1* translocation has been reported in two polyphenotypic tumors and two rhabdomyosarcomas.^[11] Cytogenetic abnormalities are highly specific to ETs; chromosome 22 is most frequently involved in structural changes detected in cells of ES. Although t(11;22) is most frequent, chromosome 22 is also involved in other translocations in neoplasia, suggesting that the break point on chromosome 22 seen in ES cells may be a more important factor in the origin of this tumor than the loci to which the deleted segment is translocated.^[1,5,6,12-14] In a case of ES which Whang-Peng *et al.*^[15] examined it had a translocation involving chromosome 6 and 12, with a break point (12p13).^[15] This finding with the absence of t(11;22) raises the possibilities that soft-tissue ES is a tumor significantly different in origin and pathogenesis from ES of the bone because our case presented with the tumor of the sacral bone. More cases need to be studied to determine the significance and incidence of this abnormality in ES. It is also important to determine whether additional structural chromosomal aberrations are present in

ES tumors because it appears that a more complex karyotype with multiple chromosomal aberrations is associated with a poor outcome in ES.^[16,17]

REFERENCES

- Iwamoto Y. Diagnosis and treatment of Ewing's sarcoma. *Jpn J Clin Oncol* 2007;37:79-89.
- Desmaze C, Brizard F, Turc-Carel C, Melot T, Delattre O, Thomas G, *et al.* Multiple chromosomal mechanisms generate an EWS/FLI1 or an EWS/ERG fusion gene in Ewing tumors. *Cancer Genet Cytogenet* 1997;97:12-9.
- Ng TL, O'Sullivan MJ, Pallen CJ, Hayes M, Clarkson PW, Winstanley M, *et al.* Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. *J Mol Diagn* 2007;9:459-63.
- Gabriela Mercado, Frederic Barr. Chromosomal Translocations in Sarcomas: New Perspectives ESUN (http://sarcomahelp.org/newsletter/february_2006.html). A periodical for sarcoma community, ESUN 2006;3:1
- Burt M, Karpeh M, Ukoha O, Bains MS, Martini N, McCormack PM, *et al.* Medical tumors of the chest wall. Solitary plasmacytoma and Ewing's sarcoma. *J Thorac Cardiovasc Surg* 1993;105:89-96.
- Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. *PLoS One* 2008;3:e1965.
- Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. *Oncogene* 2010;29:4504-16.
- Gorello P, La Starza R, Mecucci C. t(12;22)(p13;q12). *Atlas Genet Cytogenet Oncol Haematol*. November 2007. (<http://AtlasGeneticsOncology.org/Anomalies/t1222p13q12ID1371.html>)
- ISCN. In: Mitelman F, editor. *An International System for Human Cytogenetic Nomenclature*. Basel: Karger; 1995.
- Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. *Cancer* 1991;67:1886-93.
- Longtin R. Ewing's sarcoma: A miracle drug waiting to happen? *J Natl Cancer Inst* 2003;95:1574-6.
- Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation,

- t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. *Nat Genet* 1994;6:146-51.
13. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, *et al.* A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. *Oncogene* 1995;10:1229-34.
 14. Sumegi J, Nishio J, Nelson M, Frayer RW, Perry D, Bridge JA. A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor. *Mod Pathol* 2011;24:333-42.
 15. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Kao-Shan S, Tsai S, *et al.* Cytogenetic characterization of selected small round cell tumors of childhood. *Cancer Genet Cytogenet* 1986;21:185-208.
 16. Zielenska M, Zhang ZM, Ng K, Marrano P, Bayani J, Ramirez OC, *et al.* Acquisition of secondary structural chromosomal changes in pediatric ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome. *Cancer* 2001;91:2156-64.
 17. Wang L, Bhargava R, Zheng T, Wexler L, Collins MH, Roulston D, *et al.* Undifferentiated small round cell sarcomas with rare EWS gene fusions: Identification of a novel EWSSP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions. *J Mol Diagn* 2007;9:498-509.

How to cite this article: Kousar Jahan SK, Mayanna MG, Kavitha BL, Patil A, Kumari P. A rare case of translocation (12;22) (p13;Q) in Ewing's sarcoma. *Indian J Med Paediatr Oncol* 2014;35:89-92.
Source of Support: Nil, **Conflict of Interest:** None declared.